BioRegenx, Inc.
BRGX
$0.01
$0.0013.92%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -20.75% | -24.56% | -26.79% | -20.09% | -31.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.75% | -24.56% | -26.79% | -20.09% | -31.41% |
| Cost of Revenue | -48.53% | -50.02% | -52.27% | -34.41% | -38.02% |
| Gross Profit | -9.33% | -12.03% | -13.34% | -13.02% | -28.25% |
| SG&A Expenses | -71.10% | -42.20% | -63.15% | -48.76% | 23.86% |
| Depreciation & Amortization | -102.22% | 0.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -73.30% | -39.83% | -50.30% | -35.04% | 30.36% |
| Operating Income | 92.08% | 48.21% | 59.83% | 41.88% | -92.16% |
| Income Before Tax | 93.30% | -285.45% | -173.53% | -209.20% | -540.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.30% | -285.45% | -173.53% | -209.20% | -540.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.30% | -285.45% | -173.53% | -209.20% | -540.39% |
| EBIT | 92.08% | 48.21% | 59.83% | 41.88% | -92.16% |
| EBITDA | 90.33% | 41.04% | 73.24% | 66.68% | -27.24% |
| EPS Basic | 93.70% | -259.02% | -126.53% | -146.81% | -373.68% |
| Normalized Basic EPS | 88.46% | 47.37% | 63.33% | 51.72% | -52.94% |
| EPS Diluted | 93.70% | -259.02% | -126.53% | -146.81% | -373.68% |
| Normalized Diluted EPS | 88.46% | 47.37% | 63.33% | 51.72% | -52.94% |
| Average Basic Shares Outstanding | 8.32% | 10.74% | 22.77% | 30.96% | 31.15% |
| Average Diluted Shares Outstanding | 8.32% | 10.74% | 22.77% | 30.96% | 31.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |